A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis.

Daniel Martin SimadibrataAri Fahrial SyamYeong Yeh Lee

Published in: Journal of gastroenterology and hepatology (2022)

Vonoprazan is superior to PPI in first-line H. pylori eradication and erosive esophagitis but non-inferior in other gastric acid-related diseases. Likewise, short-term safety is comparable in both treatment groups.

Keyphrases

helicobacter pylori
protein protein
angiotensin ii
replacement therapy